Background: Understanding the attack rate of influenza infection and the proportion who become ill by risk group is key to implementing prevention measures. While population-based studies of antihemagglutinin antibody responses have been described previously, studies examining both antihemagglutinin and antineuraminidase antibodies are lacking. Methods: In 2015, we conducted a seroepidemiologic cohort study of individuals randomly selected from a population in New Zealand. We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion. We followed participants weekly and performed influenza polymerase chain reaction (PCR) for those reporting influenza-like illness (ILI). Results: Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence interval, 32%-38%]) of 911 unvaccinated participants, of whom 100 (31%) seroconverted to NAI alone. Young children and Pacific peoples experienced the highest influenza infection attack rates, but overall only a quarter of all infected reported influenza PCR-confirmed ILI, and one-quarter of these sought medical attention. Seroconversion to NAI alone was higher among children aged <5 years vs those aged ≥5 years (14% vs 4%; P < .001) and among those with influenza B vs A(H3N2) virus infections (7% vs 0.3%; P < .001). Conclusions: Measurement of antineuraminidase antibodies in addition to antihemagglutinin antibodies may be important in capturing the true influenza infection rates.
Background: Understanding the attack rate of influenza infection and the proportion who become ill by risk group is key to implementing prevention measures. While population-based studies of antihemagglutinin antibody responses have been described previously, studies examining both antihemagglutinin and antineuraminidase antibodies are lacking. Methods: In 2015, we conducted a seroepidemiologic cohort study of individuals randomly selected from a population in New Zealand. We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion. We followed participants weekly and performed influenza polymerase chain reaction (PCR) for those reporting influenza-like illness (ILI). Results: Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence interval, 32%-38%]) of 911 unvaccinated participants, of whom 100 (31%) seroconverted to NAI alone. Young children and Pacific peoples experienced the highest influenza infection attack rates, but overall only a quarter of all infected reported influenza PCR-confirmed ILI, and one-quarter of these sought medical attention. Seroconversion to NAI alone was higher among children aged <5 years vs those aged ≥5 years (14% vs 4%; P < .001) and among those with influenza B vs A(H3N2) virus infections (7% vs 0.3%; P < .001). Conclusions: Measurement of antineuraminidase antibodies in addition to antihemagglutinin antibodies may be important in capturing the true influenza infection rates.
Authors: Elizabeth Miller; Katja Hoschler; Pia Hardelid; Elaine Stanford; Nick Andrews; Maria Zambon Journal: Lancet Date: 2010-01-21 Impact factor: 79.321
Authors: Don Bandaranayake; Q Sue Huang; Ange Bissielo; Tim Wood; Graham Mackereth; Michael G Baker; Richard Beasley; Stewart Reid; Sally Roberts; Virginia Hope Journal: PLoS One Date: 2010-10-14 Impact factor: 3.240
Authors: Maria D Van Kerkhove; Siddhivinayak Hirve; Artemis Koukounari; Anthony W Mounts Journal: Influenza Other Respir Viruses Date: 2013-01-21 Impact factor: 4.380
Authors: Barney I Potter; Rebecca Kondor; James Hadfield; John Huddleston; John Barnes; Thomas Rowe; Lizheng Guo; Xiyan Xu; Richard A Neher; Trevor Bedford; David E Wentworth Journal: Virus Evol Date: 2019-12-04
Authors: Jackson S Turner; Tingting Lei; Aaron J Schmitz; Aaron Day; José Alberto Choreño-Parra; Luis Jiménez-Alvarez; Alfredo Cruz-Lagunas; Stacey L House; Joaquín Zúñiga; Ali H Ellebedy; Philip A Mudd Journal: J Infect Dis Date: 2020-09-01 Impact factor: 5.226
Authors: Jerome I Tokars; Manish M Patel; Ivo M Foppa; Carrie Reed; Alicia M Fry; Jill M Ferdinands Journal: Clin Infect Dis Date: 2020-12-17 Impact factor: 9.079
Authors: Daniel Reynolds; Cristina Vazquez Guillamet; Aaron Day; Nicholas Borcherding; Rodrigo Vazquez Guillamet; José Alberto Choreño-Parra; Stacey L House; Jane A O'Halloran; Joaquín Zúñiga; Ali H Ellebedy; Derek E Byers; Philip A Mudd Journal: J Immunol Date: 2021-08-04 Impact factor: 5.426
Authors: James A Hay; Amanda Minter; Kylie E C Ainslie; Justin Lessler; Bingyi Yang; Derek A T Cummings; Adam J Kucharski; Steven Riley Journal: PLoS Comput Biol Date: 2020-05-04 Impact factor: 4.779